- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05057858
The Women TDF-FTC Benchmark Study
Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, randomized, three-arm, directly observed therapy study. HIV-uninfected non-pregnant cisgender women at low risk for HIV will be randomly assigned to 1 of 3 dosing frequencies of directly observed therapy (DOT) Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) PrEP to help differentiate poor and modest from perfect dosing. An additional contemporaneous cohort of pregnant to receive daily dosing will also be recruited to evaluate the impact of pregnancy on blood and cellular drug levels. Drug concentrations in blood, vaginal fluid, and tissue will be measured during the study. The primary objectives of the study are:
- To define the cisgender women-specific expected blood concentrations and dose-proportionality for Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) and Peripheral Blood Mononuclear Cells(PBMCs) using directly observed TDF/FTC therapy at 2, 4, 7 doses per week.
- To establish a model to predict adherence rate to TDF/FTC by level of TFV-DP in DBS for cisgender women. HIV-uninfected non-pregnant cisgender women will be randomly assigned to 1 of 3 dosing frequencies of directly observed therapy (DOT) TDF/FTC PrEP: 2, 4, or 7 doses/week to help differentiate poor and modest from perfect adherence.
The study will be the first to define TDF-PrEP adherence-blood concentration thresholds for African cisgender women, a priority population for HIV prevention. The findings will guide accurate interpretation of adherence and success of PrEP programs in cisgender women. This data will also help guide decisions on optimal PrEP dosing for HIV at-risk pregnant cisgender women in Africa.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Thika, Kenya
- Kenya Medical Research Institute - Partners in Health Research and Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 and ≤30 years old
- Willing to undergo urine pregnancy tests
- Has understood the information provided and has provided written informed consent before any study-related procedures are performed.
- HIV uninfected based on negative HIV rapid tests, according to Kenyan national algorithm
- Normal renal function (estimated glomerular filtration rate >60 mL/min)
- Hepatitis B surface Ag negative
- No active clinically significant medical or psychiatric conditions that would interfere with study participation
- Lack of severe anemia
- Willing to use DOT and come to clinic frequently for DOT PrEP for at least 8 weeks
- Willing to have home visits for follow up
- Has access to an active smartphone to allow off-site observation of dosing if unable to come to the clinic or as determined by the study staff, the participant resides in close location to clinic to permit home visit if unable to come to the clinic. i.e., potential participants without a smartphone may be enrolled in the study if investigator determines that the participant resides within reasonable distance from the clinic that would permit home visit id the participant misses their visit.
- Intention to stay within the study site's catchment area for at least 8 weeks.
- Resides or works in catchment area with high speed internet coverage to permit video streaming
Specific for non-pregnant cisgender women cohort
- Not pregnant or breast feeding
- At low risk for HIV. In Kenya, national guidelines define substantial risk for HIV and recommend PrEP be an option for individuals reporting: partner of HIV-infected person not on ART or on ART for <6 months, >1 partner of unknown status, transactional sex, recent STI, recurrent PEP use, inconsistent condom use, or injection drug use. So, non-pregnant cisgender women reporting any of these factors will not be eligible for the study but will be linked for PrEP at clinic of choice including at Thika Site itself.
- Willing to be randomized to non-daily PrEP and come to clinic frequently for DOT PrEP
- Willingness and ability to be abstinent for at least 7 days after each vaginal biopsy visit.
Specific for pregnant cisgender women only
- At screening, evidence of a viable pregnancy with gestational age of 13-26 weeks after the date of conception with sonographic confirmation. If adequate sonographic results are not available from medical records at screening, an ultrasound must be performed in the interim so that the result is available at study entry.
- At elevated risk for acquiring HIV according to Kenya guideline for PrEP. This is to ensure an ethical approach for provision of PrEP in pregnancy (i.e., only exposing PrEP to those who want and might benefit from it). Kenya national guidelines define substantial risk for HIV and recommend PrEP be an option for individuals reporting partner of HIV-infected person not on ART or on ART for <6 months, >1 partner of unknown status, transactional sex, recent STI, recurrent PEP use, no or inconsistent condom use
- At study entry, willing to use PrEP during pregnancy for HIV prevention
Exclusion Criteria:
- For all cisgender women
- Inability to give informed consent
- Positive screening HIV+ as determined by standard rapid serologic assays or suspected acute HIV infection in the opinion of the clinician. (example signs and symptoms of acute HIV infection include combinations of fever, headache, fatigue, arthralgia, vomiting, myalgia, diarrhea, pharyngitis, rash, night sweats, and adenopathy cervical or inguinal)
- Positive HBV surface antigen test at screening
- Calculated creatinine clearance < 60 ml/min.
- Any laboratory value or uncontrolled medical conditions that, in the opinion of the investigators, would interfere with the study conditions such as, heart disease and/or cancer.
- Prohibited concomitant medications are: investigational agents (within 30 days of enrollment), aminoglycosides, ganciclovir/valganciclovir, chronic high-dose acyclovir/valacyclovir (>800mg acyclovir or > 500mg valacyclovir for >7 days), cyclosporine, amphotericin B, foscarnet, and cidofovir, and products with same or similar active ingredients as the study medications including TAF®, ATRIPLA®, COMPLERA®, EMTRIVA®, VIREAD®; or drugs containing lamivudine or adefovir, which are close analogs of FTC and tenofovir, respectively.
- Current or past use of PrEP (pre-exposure prophylaxis)
- Not willing to have home visits
Specific for non-pregnant cisgender women cohort
- Pregnancy or plan to become pregnant in the next 6 months or unwillingness to use birth control
- Current breastfeeding
- High risk of HIV infection (for example: sexually active with an HIV infected partner; engages in condomless intercourse with HIV-infected partners or partner of unknown status during the study; females who exchange sex for money, shelter, or gifts; active injection drug use or during the last 12 months; newly diagnosed sexually transmitted infections in last 6 months.
Specific for pregnant cisgender women cohort
- Mother has a known history of any of the following, as determined by the site investigator or designee based on maternal report and available medical records:
- Sickle cell anemia (excluding sickle cell trait), chronic bleeding, blood transfusion within the past 120 days (excluding for chronic illness) or other blood dyscrasias
- Fetus has a known or suspected major congenital anomaly, from chart review of prior data, defined ultrasound.
- Complications in prior pregnancies that would be considered exclusionary
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Perfect Adherence
Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
|
Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Other Names:
|
Experimental: Moderate Adherence
Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
|
Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Other Names:
|
Experimental: Poor Adherence
Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
|
Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steady state concentrations of tenofovir-diphosphate for different dosing patterns of DOT TDF/FTC PrEP
Time Frame: Assessed through 8 weeks
|
Measured in dried blood spots, whole blood, PBMCs
|
Assessed through 8 weeks
|
Steady state concentrations of tenofovir for different dosing patterns of DOT TDF/FTC PrEP
Time Frame: Assessed through 8 weeks
|
Measured in plasma, whole blood, vaginal tissue
|
Assessed through 8 weeks
|
Composite outcome of adverse pregnancy outcomes among pregnant women who used DOT PrEP
Time Frame: Assessed at delivery (approximately through 40 weeks gestation)
|
Descriptive frequency indicating presence vs. absence of any adverse pregnancy outcomes.
Adverse outcomes are defined as at least one of the following: spontaneous abortion (less than 20 weeks gestation), stillbirth (greater than or equal to 20 weeks gestation), preterm delivery (less than 37 weeks), or small for gestational age (less than 10th percentile using WHO norms)
|
Assessed at delivery (approximately through 40 weeks gestation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Grade 2 or higher adverse events in participants
Time Frame: Assessed through 8 weeks of DOT TDF/FTC PrEP
|
Based on signs, symptoms, labs, and diagnoses
|
Assessed through 8 weeks of DOT TDF/FTC PrEP
|
Frequency of infant death among infants of women in the pregnant cohort
Time Frame: Assessed through 12 months after delivery
|
Based on safety-related data recorded on case report forms and complete expedited adverse event (EAE) reporting by site investigators
|
Assessed through 12 months after delivery
|
Frequency of infant Grade 2 or higher adverse events among infants of women in the pregnant cohort
Time Frame: Assessed through 12 months after delivery
|
Assessed according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017
|
Assessed through 12 months after delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter L Anderson, PharmD, University of Colorado, Denver
- Principal Investigator: Kenneth K Mugwanya, MBChB, MS, PhD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- STUDY00011136
- R01AI155086 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on co-formulated 300 mg TDF/ 200mg FTC
-
Yonsei UniversityUnknown
-
University of WashingtonUniversity of Colorado, Denver; Gilead Sciences; Kenya Medical Research InstituteCompleted
-
Professor Francois VenterCompletedHIV-1 InfectionSouth Africa
-
ANRS, Emerging Infectious DiseasesGilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaboratorsNot yet recruiting
-
Gilead SciencesCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH); Impact Research & Development OrganizationCompleted
-
Rush University Medical CenterMerck Sharp & Dohme LLCWithdrawnHIV-1 InfectionsUnited States
-
Rockefeller UniversityMerck Sharp & Dohme LLC; Pfizer; Aaron Diamond AIDS Research CenterCompleted
-
Merck Sharp & Dohme LLCCompleted